 Connection
Bradley Haverkos to Retrospective Studies
This is a "connection" page, showing publications Bradley Haverkos has written about Retrospective Studies.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.226 |
|
|
|
-
Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017 07 13; 130(2):221-228.
Score: 0.036
-
Haverkos BM, Gru AA, Geyer SM, Bingman AK, Hemminger JA, Mishra A, Wong HK, Pancholi P, Freud AG, Caligiuri MA, Baiocchi RA, Porcu P. Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S181-S190.e4.
Score: 0.034
-
Haverkos B, Tyler K, Gru AA, Winardi FK, Frederickson J, Hastings J, Elkins C, Zhang X, Xu-Welliver M, Wong HK, Porcu P. Primary Cutaneous B-Cell Lymphoma: Management and Patterns of Recurrence at the Multimodality Cutaneous Lymphoma Clinic of The Ohio State University. Oncologist. 2015 Oct; 20(10):1161-6.
Score: 0.032
-
Gauthier J, Ahn KW, Patel J, Lian Q, Badawy S, Cairo MS, Delgado J, Grover N, Haverkos B, de Lima M, Malone A, Mussetti A, Nieto Y, Pawarode A, Pearson L, Solh M, Sureda A, Tun AM, Wudhikarn K, Yamshon S, Shadman M, Turtle CJ, Hamadani M, Herrera AF. CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis. Am J Hematol. 2025 10; 100(10):1792-1802.
Score: 0.016
-
Epperla N, Zayac AS, Landsburg DJ, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman A, Li S, Medeiros LJ, Chang JE, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi Y, Bond DA, Evens AM, Naik SG, Kamdar M, Haverkos BM, Karmali R, Farooq U, Vose JM, Rubinstein P, Chaudhry A, Olszewski AJ. High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series. Blood Adv. 2024 10 22; 8(20):5355-5364.
Score: 0.015
-
Allen J, Abbott D, Eskandar J, Bair SM, Haverkos B, Jasem J, Kamdar M, Major A. DA-R-EPOCH May Mitigate the Adverse Prognostic Implication of the Diagnosis-to-Treatment Interval (DTI) in Large B-Cell Lymphomas. Clin Lymphoma Myeloma Leuk. 2025 Jan; 25(1):e26-e33.
Score: 0.015
-
Kent A, Gil KB, Jones MK, Linden B, Purev E, Haverkos B, Schwartz M, McMahon C, Amaya M, Smith CA, Bosma G, Abbott D, Rabinovitch R, Milgrom SA, Pollyea DA, Gutman JA. Outcomes of Haplo-Cord Versus Dual Cord Transplants: A Single-Center Retrospective Analysis. Transplant Cell Ther. 2025 Apr; 31(4):267.e1-267.e11.
Score: 0.015
-
Colton M, Purev E, Haverkos B, Bair S, Jasem J, Jacob A, Kamdar M. Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy. Clin Lymphoma Myeloma Leuk. 2024 Nov; 24(11):778-782.
Score: 0.015
-
Zayac AS, Landsburg DJ, Hughes ME, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Epperla N, Bond DA, Farooq U, Saad M, Evens AM, Pandya K, Naik SG, Kamdar M, Haverkos B, Karmali R, Oh TS, Vose JM, Nutsch H, Rubinstein PG, Chaudhry A, Olszewski AJ. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Adv. 2023 11 14; 7(21):6381-6394.
Score: 0.014
-
Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar MK, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson S, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas Bisneto JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade MJ, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline J. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023 08 22; 7(16):4528-4538.
Score: 0.014
-
Cortese MJ, Wei W, Cerdeña S, Watkins MP, Olson M, Jodon G, Kaiser J, Haverkos B, Hughes ME, Namoglu E, Grover NS, Snow A, Orellana-Noia V, Rainey M, Sohail M, Rudoni J, Portell C, Voorhees T, Landsburg DJ, Kamdar M, Kahl BS, Hill BT. A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma. Leuk Lymphoma. 2023 01; 64(1):107-118.
Score: 0.013
-
Sharma P, Pollyea DA, Smith CA, Purev E, Kamdar M, Haverkos B, Sherbenou D, Rabinovitch R, Hammes A, Gutman JA. Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison. Biol Blood Marrow Transplant. 2018 08; 24(8):1671-1677.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|